Home Cart Sign in  
Chemical Structure| 256373-96-3 Chemical Structure| 256373-96-3

Structure of MCC950 sodium
CAS No.: 256373-96-3

Chemical Structure| 256373-96-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MCC950 sodium (CRID3 sodium salt) is an effective and selective NLRP3 inhibitor with IC50 values of 7.5 nM in BMDMs and 8.1 nM in HMDMs.

Synonyms: CP-456773 sodium; CRID3 sodium salt; CP 456,773

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MCC950 sodium

CAS No. :256373-96-3
Formula : C20H23N2NaO5S
M.W : 426.46
SMILES Code : CC(O)(C1=COC(S(=O)([N-]C(NC2=C3CCCC3=CC4=C2CCC4)=O)=O)=C1)C.[Na+]
Synonyms :
CP-456773 sodium; CRID3 sodium salt; CP 456,773
MDL No. :MFCD30478884
InChI Key :LFQQNXFKPNZRFT-UHFFFAOYSA-M
Pubchem ID :91826093

Safety of MCC950 sodium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary PBMC 1 μM 24 h Tested the effect of MCC950 in LPS-stimulated PBMC, results showed MCC950 had no preventive effect on cell death PMC8782710
THP1 monocytic cells 1 μM Tested the effect of MCC950 in THP1 cells, results showed MCC950 had no preventive effect on cell death PMC8782710
BV2 microglia 10 µM 30 min To evaluate the effect of MCC950 on sevoflurane-induced inflammation in BV2 microglia. Results showed that MCC950 pretreatment significantly inhibited sevoflurane-induced NLRP3 inflammasome activation. PMC10929193
PDL progenitor cells 10 μM 6 h To investigate the regulation of force-induced pyroptosis in PDL progenitor cells, MCC950 partially suppressed the expression of pyroptosis-related proteins PMC10788340
B-lymphocytes 100 µM 24 h Inhibition of NLRP3 inflammasome, reducing IL-1β secretion PMC5684107

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Orthodontic tooth movement model Intraperitoneal injection 20 mg/kg Every two days for 7 days To investigate the influence of pyroptosis level on orthodontic tooth movement, MCC950 inhibited the expression of pyroptosis-related markers and reduced the tooth movement distance PMC10788340
Mice DSS-induced colitis model Intraperitoneal injection 20 mg/kg Once daily for 2 days MCC950 significantly alleviated C. difficile-induced colitis, reducing neutrophil accumulation and inflammatory responses PMC10038061
Mice Pml−/− mouse model Intraperitoneal injection 20 mg/kg Single injection MCC950, as an NLRP3 inhibitor, was able to suppress NLRP3 activation in Pml?/? mice, thereby reducing IL-1β release. PMC9713080
Mice Dsg2mut/mut mice Subcutaneous injection 5 mg/kg Continuous for 4 weeks Inhibition of NLRP3 inflammasome significantly alleviates right ventricular dilation and dysfunction PMC10773142

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.34mL

0.47mL

0.23mL

11.72mL

2.34mL

1.17mL

23.45mL

4.69mL

2.34mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories